𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Liver histology in patients with HBsAg negative anti-HBc and anti-HCV positive chronic hepatitis

✍ Scribed by Evangelista Sagnelli; Giuseppe Pasquale; Nicola Coppola; Cecilia Marrocco; Ferdinando Scarano; Michele Imparato; Caterina Sagnelli; Carlo Scolastico; Felice Piccinino


Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
71 KB
Volume
75
Category
Article
ISSN
0146-6615

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

The liver histology of 68 consecutive anti‐HCV/HCV‐RNA positive chronic hepatitis patients who were HBsAg/anti‐HBs negative, anti‐HBc positive (Case bC group) was compared with that of 68 anti‐HCV/HCV‐RNA positive chronic hepatitis patients who were HBsAg/anti‐HBc negative (control C group). The patients were pair‐matched by age (±5 years), sex, and risk factors for the acquisition of parenteral infection. Case bC group showed a significantly higher mean fibrosis score (2.3 ± 1.1) than control C group (1.5 ± 1.1, P < 0.001) and more histological evidence of cirrhosis (22% vs. 7.3%, P < 0.05). In addition, the patients in Case bC group showed more severe inflammation of the portal tracts (3.5 ± 0.8 vs. 3.0 ± 1.1, P < 0.005) and there was a higher prevalence of patients with rhomboid‐shaped hepatocytes (26.4% vs. 2.7%, P < 0.005), acidophilic bodies (33.8% vs. 1.4%, P < 0.0001), sinusoidal inflammation (29.4% vs. 10.3%, P < 0.01), lymphoid follicles in the portal tracts (72% vs. 44.1%, P < 0.05), Kupffer cell proliferation (29.4% vs. 11.8%, P < 0.05), bile duct damage (44.1% vs. 10.3%, P < 0.0001), and ductular proliferation (30.9% vs. 2.7%, P < 0.001) than in control C group. No difference in these histological features was observed between HBV‐DNA negative and positive patients in Case bC group. The data suggest that anti‐HBc positive patients with HCV chronic infection have a significantly higher degree of liver fibrosis, and that hepatocellular apoptosis, bile duct damage, and ductular proliferation correlate with the presence of this antibody in the serum. J. Med. Virol. 75:222–226, 2005. © 2004 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


IgM anti-HBc in anti-HBe positive chroni
✍ Kazuhiko Koike; Shiro Iino; Kiyohiko Kurai; Keiji Mitamura; Yasuo Endo; Hiroshi 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 408 KB 👁 1 views

IgM anti-HBc was measured by radioimmunoassay in se~rially collected serum samples during 20 acute exacerbations which developed in 14 patients with anti-HBe paeitive chronic type B hepatitis. IgM anti-HBc became @the in 12 of the 14 (86%) patients and in 18 of the 20 (90%) exacerbations, and elevat

Hepatitis D virus antibody in HBsAg-posi
✍ Dr. David M. Novick; Patrizia Farci; Peter Karayiannis; Alvin M. Gelb; Richard J 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 383 KB

The hepatitis D virus (HDV; previously called the "delta agent") is a defective organism which can replicate only in the presence of the hepatitis B virus (HBV). We tested the serum of 95 substance abusers, all of whom had sufficient evidence of chronic liver disease to warrant a liver biopsy, for h

Interferon vs. adenine arabinoside 5′-mo
✍ Buti, Maria; Jardi, Rosendo; Rodriguez-Frias, Francisco; Allende, Helena; Cotrin 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 393 KB 👁 1 views

Anti-HBe-positive patients with precore mutants may have severe, progressive liver disease. Therapy with interferon has been effective, but relapses are frequent. To evaluate and compare two antiviral treatments, lymphoblastoid interferon fly-IFN) and adenine arabinoside 5'-monophosphate (ARA-AMP),